Serological and Laboratory Profile of Individuals with Latent form of Ebola Virus Disease in an Endemic region of West Africa

Relevance. Due to its high mortality rate and the risk of widespread spread, Ebola virus (EV) disease remains a major global health problem. Of great importance is the study of the characteristics of asymptomatic forms of the disease, which occur with high frequency in endemic regions.
Aim. To retrospectively evaluate the characteristics of population immunity and some laboratory parameters in individuals who have suffered a latent form of the disease caused by the Ebola virus (EB).
Materials and methods. To determine the proportion of individuals who have specific antibodies to the Ebola virus, 1079 volunteers living in the Kindia prefecture of the Republic of Guinea were examined from August 2017 to July 2018. To further assess the clinical and laboratory characteristics of seropositive cases, the study group (immune individuals, n=58) were compared according to basic epidemiological, clinical and laboratory parameters with a comparison group (healthy volunteers, n = 121).
Results. The proportion of seropositive individuals from the study sample was 8.6%. Most of the individuals in the study group lived in the Kindia city setting. The largest number of seropositive cases was observed among older patients. Among immune individuals, there were higher relative values of blood lymphocytes and lower relative values of segmented neutrophils, and a statistically significant higher content of leukocytes in the urine. The values of the parameters of the biochemical blood test did not exceed the reference limits.
Conclusion. The characteristics of population immunity and clinical and laboratory signs of the disease caused by the Ebola virus in individuals from a separate endemic region have been established.

1. Sospeter S.B., Udohchukwu O.P., Ruaichi J., et al. Ebola outbreak in DRC and Uganda; an East African public health concern. Health Sci Rep. 2023. Vol. 31, N6(8). P. 1448. doi: 10.1002/hsr2.1448.

2. Kuhn J.H., Andersen K.G., Baize S., et al. Nomenclature and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses. 2014. Vol. 6, N11. P. 4760–4799. doi:10.3390/v6114760

3. Krasnov Y.M., Safronov V.A., Nosov N.Yu., Kutyrev V.V., Popova A.Yu. Comparative Analysis of the Sequenced Zaire ebolavirus Samples from the Republic of Guinea. Problems of Particularly Dangerous Infections. 2015;(3):65–72. (In Russ.). https:.doi.org/10.21055/0370-1069-2015-3-65-72

4. Simon-Loriere E., Faye O., Faye O. et al. Distinct lineages of Ebola virus in Guinea during the 2014 West African epidemic. Nature. 2015. Vol. 524, N7563. P. 102–104. https:.doi. org/10.1038/nature14612

5. Baize S., Pannetier D., Oestereich L., et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 2014. Vol. 371, N15. P. 1418–1425. doi: 10.1056/NEJMoa1404505

6. Mari Saez A., Weiss S., Nowak K., et al. Investigation the zoonotic origin of the West African Ebola Epidemic. EMBO Mol. Med. 2015. Vol. 7, N1. P. 17–23. doi: 10.15252/emmm.201404792

7. Zhdanov K.V., Holikov I.V. Disease caused by the Ebola virus: from theory to practice. Journal Infectology. 2015;7(1):5–17. (In Russ.). https:.doi.org/10.22625/2072-6732-2015-7-1-5-17

8. Nechaev V.V., Zdanov K.V., Grishanova G.I. Сharacterization of epidemic called Ebola virus in West Africa. Journal Infectology. 2015;7(2):21–30. (In Russ.). https:.doi. org/10.22625/2072-6732-2015-7-2-21-30

9. Shhelkanov M.Ju., Zumanigi N., Buaro M.J., et al. Pjat’ mifov o lihoradke Jebola: gde konchaetsja vymysel? Aktual’nye infekcii v Gvinejskoj Respublike: jepidemiologija, diagnostika i immunitet. SPb: FBUN NIIJeM imeni Pastera; 2017: 75–83. (In Russ.).

10. Chertow D.S., Kleine S., Edwards J.K., et al. Ebola virus disease in West Africa – clinical manifestations and management. N. Engl. J. Med. 2014. Vol. 371, N22. Р. 2054–2057. doi: 10.1056/NEJMp1413084

11. Maleev V.V., Tolno F., Konomou K.V., et al. Epidemiological Peculiarities and Clinical Features of Ebola Virus Disease in the Republic of Guinea. Problems of Particularly Dangerous Infections. 2015;(3):27–32. (In Russ.) https:.doi.org/10.21055/0370-1069-2015-3-27-32

12. Zhdanov K.V., Zakharenko S.M., Kovalenko A.N., et al. Ebola hemorrhagic fever: etiology, pathogenesis and clinical symptoms. Klin. med. 2015; 93(8):23–29. (in Russ).

13. Zhdanov K.V., Shhjogolev A.V., Kovalenko A.N., et al. Terapija gemorragicheskoj lihoradki Ebola. Voenno-medicinskij zhurnal. 2015;336(11):48–53. (In Russ).

14. Sobarzo A., Ochayon D.E., Lutwama J.J., et al. Persistent immune responses after Ebola virus infection. N. Engl. J. Med. 2013. Vol. 369, N5. Р. 492–493. doi: 10.1056/NEJMc1300266

15. McElroy A.K., Akondy R.S., Davis S.W., et al. Human Ebola virus infection results in substantial immune activation. J. Virol. 2004. Vol. 78, N19. Р. 10370–10377. DOI: 10.1128/jvi.78.19.10370-10377.2004. doi: 10.1073/pnas.1502619112

16. Bellan S.E., Pulliam J.R.C., Dushoff J., et al. Ebola control: effect of asymptomatic infection and acquired immunity. The Lancet. 2014. Vol. 84, N9953, P. 1499–1500. doi: 10.1016/S0140-6736(14)61839-0

17. Malcev O.V., Gudkov R.V., Gabdrahmanov I.A., et al. Naprjazhennost’ populjacionnogo immuniteta k nekotorym virusnym gemorragicheskim lihoradkam v prefekture Kindija Respubliki Gvineja. Journal Infectology. 2018;10(2);1:74–75. (In Russ).

18. Varkey J.B., Shantha J.G., Crozier I., et al. Persistence of Ebola virus in ocular fluid during convalescence. N. Engl. J. Med. 2014. Vol. 372, N25. Р. 2423–2427. DOI: 10.1056/NEJMoa1500306. doi: 10.1056/NEJMoa1500306

19. Moreau M., Spencer C., Gozalbes J.G., et al. Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient. Euro Surveill. 2015. Vol. 20, N3. Р. 10–12. doi: 10.2807/1560-7917.es2015.20.3.21017

20. Geisbert T.W. Marburg and Ebola Hemorrhagic Fever (Filoviruses). In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 8th edition. Philadelphia: Elsevier; 2015

21. Bodur H., Akinci E., Ascioglu S., et al. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg Infect Dis. 2012. Vol. 18, N4. P. 640–642. doi:10.3201/eid1804.111374

22. Heffernan R.T., Pambo B., Hatchett R.J., et al. Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 1997. J Infect Dis. 2005. Vol. 15, N6. P. 964–968. doi: 10.1086/427994

23. Leroy E.M., Baize S., Volchkov V.E., et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000. Vol. 24, N355. P. 2210–2215. doi: 10.1016/s0140-6736(00)02405-3